In a report released today, Steven Lichtman from Oppenheimer assigned a Buy rating to MannKind (MNKD), with a price target of $7.00. The company’s shares closed last Tuesday at $5.48, close to its 52-week high of $6.13.
According to TipRanks.com, Lichtman is a 5-star analyst with an average return of 16.8% and a 58.2% success rate. Lichtman covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Integra Lifesciences, and Boston Scientific.
MannKind has an analyst consensus of Moderate Buy, with a price target consensus of $5.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $6.13 and a one-year low of $0.80. Currently, MannKind has an average volume of 4.94M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
MannKind Corp. is a biopharmaceutical company. It focuses on the discovery, development and, commercialization of therapeutic products for diseases, such as diabetes and cancer. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Westlake Village, CA.
